Interview, Fireside Chat
Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo
- GLP-1 drug utilization is projected to grow significantly as employer-sponsored insurance coverage expands from the current ~25% to become more mature and accessible.
- Approval of lower-cost GLP-1 variants is anticipated within the next several years, potentially reaching price points that offer financial benefits to health plans.
- Hundreds of cell and gene therapies are expected to face financial strain and potential insolvency soon if current approval costs and single-patient reimbursement models remain unchanged.
- Dozens of new cell and gene therapy drugs are projected to be approved and launched over the next several years.
- The FDA is expected to implement significant regulatory changes regarding the approval and ongoing monitoring of cell and gene therapies.
- CMS is expected to introduce a near-future program providing guidance on financing and administering advanced therapies.
- CMS policy changes are anticipated to proceed slowly during the election year before industry pressure accelerates an innovation cycle.
- A holistic ecosystem solution is expected to emerge from entrepreneurs connecting payers, providers, manufacturers, and patients to resolve the "cold start problem" at scale.
- The healthcare system faces a risk of bankruptcy or structural failure unless new financing mechanisms and operational capabilities are developed to manage the costs and logistics of high-value therapies.
- The system is expected to continue experiencing insurance denials and coverage barriers for GLP-1s and cell/gene therapies until reimbursement models undergo fundamental redesign.